Targretin is a cancer medicine used for the treatment of the visible signs on the skin of cutaneous T-cell lymphoma (CTCL). CTCL is a rare type of lymphoma (cancer of the lymph tissue) where some white blood cells (T-cells) grow in the skin. Targretin is used in patients who have an advanced disease and have had at least one other treatment.
Targretin : EPAR - Medicine overview (PDF/74.6 KB)
First published: 20/04/2009
Last updated: 28/06/2018
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
Lymphoma, T-Cell, Cutaneous
|Anatomical therapeutic chemical (ATC) code||
|Date of issue of marketing authorisation valid throughout the European Union||
21/06/2021 Targretin - EMEA/H/C/000326 - IA/0060
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Targretin capsules are indicated for the treatment of skin manifestations of advanced stage cutaneous T-cell lymphoma (CTCL) patients refractory to at least one systemic treatment.